Disrupting this loop by the FDA-approved CCR5 inhibitor (CCR5i) maraviroc reduces pancreatic tumor cell migration, invasiveness (Singh et al., 2018), and proliferation (Huang et al., 2020). The gene discussed is CCR5; the disease is pancreatic neoplasm.